-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Mvabea + Zabdeno in Ebolavirus Infections (Ebola Hemorrhagic Fever)
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Mvabea + Zabdeno in Ebolavirus Infections (Ebola Hemorrhagic Fever) Drug Details: Ebola [ankara bavarian nordic...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – GS-6779 in Hepatitis B
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data.GS-6779 in Hepatitis BDrug Details:GS-6779 is under development for the prevention of hepatitis B. The vaccine...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – HPV Induced Cancers in Human Papillomavirus (HPV) Associated Cancer
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. HPV Induced Cancers in Human Papillomavirus (HPV) Associated Cancer Drug Details: Vaccine candidate is...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – TK-001 in Breast Cancer
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. TK-001 in Breast Cancer Drug Details: TK-001 is under development for the treatment of...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Human Immuno Deficiency Virus Vaccine in Human Immunodeficiency Virus (HIV) Infections (AIDS)
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.Human Immuno Deficiency Virus Vaccine in Human Immunodeficiency Virus (HIV) Infections (AIDS) Drug Details: Vaccine candidate...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – VTP-300 in Hepatitis B
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data.VTP-300 in Hepatitis BDrug Details:VTP-300 is under development for the treatment of hepatitis B. It is...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – ATP-152 in Pancreatic Ductal Adenocarcinoma
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data.ATP-152 in Pancreatic Ductal AdenocarcinomaDrug Details:ATP-152 is under development for the treatment of KRAS G12D and...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – ATP-150 in Pancreatic Ductal Adenocarcinoma
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data.ATP-150 in Pancreatic Ductal AdenocarcinomaDrug Details:ATP-150 is under development for the treatment of KRAS G12D and G12V...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – SLATE-001 in Solid Tumor
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. SLATE-001 in Solid Tumor Drug Details: SLATE-001 is under development for the treatment of...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – SLATE-001 in Metastatic Colorectal Cancer
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. SLATE-001 in Metastatic Colorectal Cancer Drug Details: SLATE-001 is under development for the treatment...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – HB-300 in Metastatic Castration-Resistant Prostate Cancer (mCRPC)
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.HB-300 in Metastatic Castration-Resistant Prostate Cancer (mCRPC) Drug Details:HB-300 is under development for the treatment of...
-
Sector Analysis
NewAzerbaijan Cards and Payments – Opportunities and Risks to 2027
Azerbaijan Cards and Payments Market Report Overview The Azerbaijan cards and payments market size is $21.3 billion in 2023. The market is expected to achieve a CAGR of more than 21% during 2023-2027. Although traditionally a cash-dominated country, Azerbaijan has been steadily observing an increase in the use of electronic payment methods such as cards. This can be attributed to the combined efforts of the government and financial institutions to boost financial awareness, improve the country’s payment infrastructure, and expand...
-
Product Insights
NewUnited Kingdom (UK) Protection Insurance – Critical Illness Market
United Kingdom (UK) Protection Insurance – Critical Illness Market Report Overview The number of contracts in the UK’s individual protection market declined by 5% in 2022 primarily due to inflation and the cost-of-living crisis that has caused financial constraints for many consumers, making it difficult to afford insurance. The number of contracts in the standalone critical illness market declined by over 4% to 70,600 in 2022. The contracts for critical illness as a rider are much larger than standalone critical...
-
Analyst Opinions
NewHow can QSRs Continue to Offer Health-Conscious Offering while Satisfying the Need for Affordable Convenience?
QSR Channel Report Overview Health has become of utmost importance, more so since the COVID-19 pandemic. It has considerably impacted the value chain of the fast-food industry. According to GlobalData's Company Filings Analytics, positive sentiment mentions of the health & wellness theme from QSRs increased significantly between 2020 and 2021. To meet healthier lifestyle expectations from consumers, restaurants have been revisiting their formulation and marketing strategies. Major players in QSR such as Domino's have continued prioritizing efficiency and affordability, but...
-
Sector Analysis
NewTrinidad and Tobago Insurance Industry – Key Trends and Opportunities to 2027
Trinidad and Tobago Insurance Industry Report Overview The total gross written premiums (GWP) in the Trinidad and Tobago insurance industry were TTD10 million in 2022 and is expected to record a CAGR of more than 5% during 2023-2027. Trinidad and Tobago is a high-income country. Its economy depends upon oil and gas exports, which contributed to real GDP growth of 2.5% in 2022. Authorities need to prioritize improving the business environment and enhancing public services, which will foster economic growth....
-
Sector Analysis
Syringes, Needles and Urinary Catheters Market Size by Segments, Share, Regulatory and Reimbursement, Procedures and Forecast to 2033
Syringes, Needles, and Urinary Catheters Market Report Overview The syringes, needles, and urinary catheters market size was $9.82 billion in 2022. They are used for a wide variety of epidemiological reasons. Prioritizing the safety of needles and syringes as well as growth in the development of clean needles and syringes will boost their sales in the forecast years. The urinary catheters market might grow in the forecast years if complications related to catheters are reduced. Moreover, the development of safer...
-
Sector Analysis
NewPower Lines in Utilities 2.0 – How Tech is Driving the Sector Innovation
Power Lines in Utilities 2.0 – How Tech is Driving the Sector Innovation Report Overview The power & utilities sector is leveraging technologies such as intelligent monitoring, digital twins, AI, robotics, and IoT to boost the efficiency, safety, and reliability of power transmission lines. These advancements aim to optimize power distribution, reduce human intervention, and create a smarter, more efficient, and reliable power system. The power lines in utilities 2.0 report also casts light on power lines-related recent developments, strategic...
-
Sector Analysis
NewUnited Kingdom (UK) Supermalls Market Size, Trends, Categories, Consumer Attitudes and Key Players to 2027
The UK Supermalls Market 2022-2027 report offers comprehensive insight and analysis of UK Supermalls (including forecasts up to 2027), the key retailers, and consumer attitudes. It provides in-depth analysis of the following: the market size and forecasts, sector performance and forecasts, retailer usage across different sectors, and consumer data. The report focuses on 7 key sectors: clothing & footwear, electricals, furniture & floorcoverings, health & beauty, homewares, and other. Consumer data is based on our 2023 UK How Britain Shops...
-
Sector Analysis
NewHungary Cards and Payments – Opportunities and Risks to 2027
Hungary Cards and Payments Market Report Overview The Hungary cards and payments market is valued at $49.6 billion in 2023. The market is expected to achieve a CAGR of more than 14% during 2023-2027. The Hungarian government and the central bank are promoting electronic payments, leading to a gradual rise in payment card acceptance. Hence, Hungarians are gradually shifting towards electronic payments and substituting cash for debit cards. This highlights consumers’ desire to avoid debt. As a result, the credit...
-
Company Profile
![]()
Becle SAB de CV – Company Profile
Becle SAB de CV (Becle) manufactures, markets and sells alcoholic, non-alcoholic beverages and ready-to-drink cocktails. Its product portfolio includes whisky, tequila, rum, brandy, vodka, margarita, and energy drinks. The company markets its products under the Jose Cuervo Especial, Jose Cuervo Tradicional, 1800, Gran Centenario, Maestro Dobel, Bushmills, Kraken, Tincup, Pendleton, The Sexton, Proper No. Twelve, Paloma, 1800 Margarita, Boost, Margarita Mix, Creyente, Boodles, Three Olives, Hanger 1, and Stranahan's brand names. It has production facilities, distilleries, bottling plants and other...
Add to Basket
Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.